- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
4
High return on equity, past performance and sound balance sheet.
4 companies
Catalyst Pharmaceuticals
Market Cap: US$3.0b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$24.20
7D
0.3%
1Y
1.0%
Exelixis
Market Cap: US$11.8b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$42.66
7D
-4.8%
1Y
29.4%
Harmony Biosciences Holdings
Market Cap: US$2.2b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$36.84
7D
0.4%
1Y
-5.1%
ACADIA Pharmaceuticals
Market Cap: US$4.4b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$25.62
7D
-4.3%
1Y
39.5%